Wide Ranks

GNFT

GENFIT S.A.

4.27

Top Statistics
Market Cap 213 M Forward PE -5.27 Revenue Growth 304.40 %
Current Ratio 3.74 Trailing PE 10.95 Earnings Growth 0.00 %
Profit Margins 27.68 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA 10.01 Enterprise / Revenue 2.72 Price To Sales Trailing12 Months 2.65
Profitability
Profit Margins 27.68 % Operating Margins 51.00 %
Balance Sheet
Total Cash 61 M Total Cash Per Share 1.24 Total Debt 67 M
Total Debt To Equity 69.64 Current Ratio 3.74 Book Value Per Share 1.96
All Measures
Short Ratio 674.00 % Message Board Id finmb_9683234 Fax 33 2 20 16 40 01
Shares Short Prior Month 74661 Return On Equity 0.2591 City Loos
Uuid 8eb2c194-ee16-3906-8e8c-31a65bed07c5 Previous Close 4.25 First Trade Date Epoch Utc 1 B
Book Value 1.96 Beta 1.12 Total Debt 67 M
Volume 4193 Price To Book 2.18 Fifty Two Week Low 3.12
Total Cash Per Share 1.24 Total Revenue 80 M Shares Short Previous Month Date 1 B
Target Median Price 9.73 Max Age 86400 Recommendation Mean 1.50
Sand P52 Week Change 0.3133 Operating Margins 51.00 % Target Mean Price 9.73
Net Income To Common 22 M Short Percent Of Float 0.0013 Implied Shares Outstanding 50 M
Trailing Peg Ratio None Last Fiscal Year End 1 B Average Daily Volume10 Day 9090
Average Volume10days 9090 Total Cash 61 M Next Fiscal Year End 1 B
Revenue Per Share 1.62 Ebitda Margins 27.16 % Trailing PE 10.95
Date Short Interest 1 B Most Recent Quarter 1 B Regular Market Previous Close 4.25
Target Low Price 7.57 Gmt Off Set Milliseconds -18000000 Fifty Day Average 5.32
Open 4.20 Free Cashflow -50663248 Dividend Yield 0.00 %
Return On Assets 0.0651 Time Zone Short Name EST Trailing Eps 0.3900
Day Low 4.18 Address1 Parc EurasantE Shares Outstanding 49 M
Price Hint 4 Target High Price 11.90 Website https://www.genfit.com
52 Week Change 0.3344 Average Volume 14346 Recommendation Key strong_buy
Forward Eps 0.0000 Compensation As Of Epoch Date 1 B Quick Ratio 364.20 %
Is_sp_500 False Regular Market Day High 4.27 Profit Margins 27.68 %
Debt To Equity 69.64 Fifty Two Week High 6.42 Day High 4.27
Shares Short 62940 Regular Market Open 4.20 Industry Key biotechnology
Earnings Growth 0.00 % Enterprise To Revenue 2.72 Revenue Growth 304.40 %
Shares Percent Shares Out 0.0013 Operating Cashflow -41542000 Currency USD
Time Zone Full Name America/New_York Market Cap 213 M Is_nasdaq_100 False
Zip 59120 Quote Type EQUITY Industry Biotechnology
Long Name Genfit S.A. Regular Market Day Low 4.18 Held Percent Institutions 0.0026
Current Price 4.27 Address2 885, avenue EugEne AvinEe Enterprise To Ebitda 10.01
Financial Currency EUR Current Ratio 3.74 Gross Margins 100.00 %
Industry Disp Biotechnology Number Of Analyst Opinions 2 Country France
Float Shares 41 M Two Hundred Day Average 4.34 Enterprise Value 218 M
Price To Sales Trailing12 Months 2.65 Forward PE -5.27 Regular Market Volume 4193
Ebitda 21 M Exchange NMS
Go to Yahoo Finance Go to Seeking Alpha 
Genfit S.

A.

, a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases.

The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis.

It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis.

The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA.

The company was incorporated in 1999 and is headquartered in Loos, France.